You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

ID: GL END 2-31 jul 2018
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
R. Goodwin, C. Agbassi, E. Kennedy, J. Biagi, R. Wong, S. Welch, S. Berry, and the Gastrointestinal Disease Site Group

Guideline Objective

The objective of this guideline is to make recommendations with respect to the role of primary tumour location (PTL) in the selection of epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and vascular endothelial growth factor (VEGF) inhibitors (first-line/second-line) in addition to chemotherapy for the treatment of unresectable metastatic colorectal cancer (mCRC).

Patient Population

The target population consists of adult patients with RAS wild-type unresectable mCRC who are undergoing first-line or second-line chemotherapy.

Intended Guideline Users

This guideline is targeted to clinicians involved in the management of patients with mCRC.

Research Questions

Are there survival and/or quality of life benefits related to the selective use of EGFR monoclonal antibodies (mAbs) and VEGF inhibitors based on PTL for the first and second-line treatment of RAS wild-type, unresectable mCRC?

pdf download Full Report (PDF) (445.18 Ko)